Long-term effectiveness, safety and adherence of bionaïve pustular psoriasis under secukinumab and ixekizumab treatment: 96-week analysis in the real-life setting

This is a real-world study to evaluate the long-term effectiveness and safety of IL-17A inhibitors for pustular psoriasis. Our findings illustrated sustained effectiveness responses through 96 weeks of treatment with SEC and IXE. Rapid improvement of GPPASI score was sustained over 96 weeks through IL-17A inhibitor therapy, but high adherence is associated with higher rates of GPPASI 100 response. SEC and IXE showed moderate but limited effectiveness for PPP. Additional information on the study design, and treatment outcomes can be found in this database.